Gangwon, Solgent Export 'COVID-19' Diagnostic Kits to the US... "Initial Shipment for 30,000 People"

[Asia Economy Reporter Hyunseok Yoo] Gangwon announced on the 23rd that it will export COVID-19 diagnostic kits to the United States.

Gangwon signed a supply contract for COVID-19 diagnostic kits with the U.S. company Cellum Bio Medical (hereinafter Cellum Bio) and agreed to supply an initial quantity sufficient for about 30,000 people. Prior to this, Gangwon signed an overseas sales contract for the diagnostic kits with Solgent on the 20th.

The ‘SOLGENT DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit’ developed by Solgent is a real-time RT-PCR (gene amplification) diagnostic kit that amplifies specific genetic sequences of COVID-19 for diagnosis. This diagnostic kit has already received emergency use authorization and export approval from the Korean Ministry of Food and Drug Safety. Following European CE certification, it obtained the first marketing authorization from the Philippine Food and Drug Administration (FDA). It is also reported to have received a request to apply for emergency use authorization from the U.S. Food and Drug Administration (FDA).

Starting with the initial supply of 30,000 units, Gangwon plans to increase the supply volume within the United States. Additionally, it is negotiating supply contracts with numerous companies in Southeast Asian countries such as China, Malaysia, the Philippines, and Thailand. In particular, concrete discussions on diagnostic kit supply are underway with China, raising expectations for rapid results. Recently, Gangwon signed a memorandum of understanding (MOU) with Sinopharm SD, China’s largest state-owned enterprise, for the supply of diagnostic kits to China.

A company official stated, “As domestic diagnostic kit technology gains global attention, inquiries about diagnostic kit supply are flooding in. Gangwon is promoting diagnostic kit supply based on a global sales network spanning about 30 countries, developed through long-term overseas plant projects. Currently, detailed discussions are underway with Europe, China, and Southeast Asian countries, so additional overseas supply expansion results are expected soon.”

He added, “Gangwon is accelerating global supply efforts centered on Solgent’s DiaPlex kit, which is recognized worldwide for its technology, and iOneBio’s rapid diagnostic kit ‘iLAMP Novel-CoV19 Detection Kit,’ which can diagnose within 20 minutes. We hope that the overseas sales of domestic diagnostic kits will contribute to calming the global pandemic emergency.”

Meanwhile, Cellum Bio, located in California, USA, is a regenerative medicine company researching and developing basic life sciences (DNA, RNA, gene expression), proteins, and delivery systems. Richard Jin, MD, Ph.D., CEO of Cellum, has conducted research in key areas such as pulmonary hypertension, cardiovascular oxidative diseases, and cellular redox mechanisms after working at Boston University School of Medicine, Harvard Medical School, and University of California, Irvine School of Medicine.

This content was produced with the assistance of AI translation services.